32 related articles for article (PubMed ID: 21484304)
1. Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.
Lamba JK; Crews KR; Pounds SB; Cao X; Gandhi V; Plunkett W; Razzouk BI; Lamba V; Baker SD; Raimondi SC; Campana D; Pui CH; Downing JR; Rubnitz JE; Ribeiro RC
Pharmacogenomics; 2011 Mar; 12(3):327-39. PubMed ID: 21449673
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial.
Liebers N; Bruch PM; Terzer T; Hernandez-Hernandez M; Paramasivam N; Fitzgerald D; Altmann H; Roider T; Kolb C; Knoll M; Lenze A; Platzbecker U; Röllig C; Baldus C; Serve H; Bornhäuser M; Hübschmann D; Müller-Tidow C; Stölzel F; Huber W; Benner A; Zenz T; Lu J; Dietrich S
Nat Cancer; 2023 Dec; 4(12):1648-1659. PubMed ID: 37783805
[TBL] [Abstract][Full Text] [Related]
3. Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy.
Brandwein JM; Gupta V; Schuh AC; Schimmer AD; Yee K; Xu W; Messner HA; Lipton JH; Minden MD
Am J Hematol; 2008 Jan; 83(1):54-8. PubMed ID: 17696207
[TBL] [Abstract][Full Text] [Related]
4. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
5. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
[TBL] [Abstract][Full Text] [Related]
6. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
[TBL] [Abstract][Full Text] [Related]
7. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
8. A prediction model for complete remission upon reinduction for patients with acute myeloid leukemia after failure of anthracycline and cytarabine standard chemotherapy.
Kim DY; Lee JH; Sym SJ; Yun SC; Lee JH; Kim SD; Choi Y; Lee YS; Kang YA; Jeon M; Seol M; Lee KH; Lee YJ; Lee KH
Ann Hematol; 2011 Nov; 90(11):1283-91. PubMed ID: 21484304
[TBL] [Abstract][Full Text] [Related]
9. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
10. Hypomethylating agents and chemotherapy in MDS.
Adès L; Santini V
Best Pract Res Clin Haematol; 2013 Dec; 26(4):411-9. PubMed ID: 24507817
[TBL] [Abstract][Full Text] [Related]
11. Is a nadir bone marrow required and, if so, what to do with residual disease?
Luger SM
Best Pract Res Clin Haematol; 2011 Dec; 24(4):527-32. PubMed ID: 22127316
[TBL] [Abstract][Full Text] [Related]
12. Are adjuncts to induction chemotherapy worthwhile in the treatment of acute myeloid leukemia?
Ravandi F
Best Pract Res Clin Haematol; 2014; 27(3-4):241-6. PubMed ID: 25455273
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]